Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes
- PMID: 23783005
- DOI: 10.1097/WNF.0b013e318296e630
Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes
Abstract
Background: Botulinum neurotoxin type A is a well-established treatment for a number of conditions involving muscle hyperactivity. Dysport (Ipsen Ltd, Wrexham, United Kingdom) is a botulinum neurotoxin type A preparation that has been available for a number of therapeutic uses for over 20 years in the European Union (EU). This survey was part of the EU botulinum toxin risk management plan to identify potential educational needs of injectors by collecting data on their routine practice administration of Dysport and their awareness of potential adverse events (AEs) that are included in the current product labeling.
Methods: Dysport-experienced injectors in 5 EU countries were surveyed via telephone about their experience of Dysport in patients with cervical dystonia, adult upper and lower limb spasticity, pediatric cerebral palsy, and blepharospasm/hemifacial spasm.
Results: The reconstitution dilution volume most often used was 2.5 mL per 500 U for all indications. The mean total dose ranged from 387 to 530 U for cervical dystonia, 508 to 773 U for upper limb spasticity, 600 to 832 U for lower limb spasticity, 375 to 700 U for pediatric cerebral palsy, and 54 to 213 U for blepharospasm/hemifacial spasm. The potential AEs most commonly mentioned by surveyed physicians were dysphagia for cervical dystonia, arm muscle weakness for upper limb spasticity, leg muscle weakness for lower limb spasticity, and pediatric cerebral palsy and ptosis for blepharospasm/hemifacial spasm.
Conclusions: The results indicate that product-labeling recommendations are generally applied in clinical practice and that there is a good familiarity with potential AEs based on clinical condition. Nevertheless, the survey shows that experienced injectors do sometimes deviate from the manufacturers labeling recommendations, highlighting the importance of ongoing education.
Similar articles
-
Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.Curr Med Res Opin. 2005 Mar;21(3):433-8. doi: 10.1185/030079905X36396. Curr Med Res Opin. 2005. PMID: 15811212 Clinical Trial.
-
Long-term Safety and Dosing of OnabotulinumtoxinA: A Prospective, Observational Study.Can J Neurol Sci. 2019 Nov;46(6):742-752. doi: 10.1017/cjn.2019.238. Can J Neurol Sci. 2019. PMID: 31256770
-
[Botulinum toxin therapy for focal dystonia].Orv Hetil. 2009 Jul 19;150(29):1381-4. doi: 10.1556/OH.2009.28640. Orv Hetil. 2009. PMID: 19581172 Hungarian.
-
[Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].Wien Klin Wochenschr. 2001;113 Suppl 4:20-4. Wien Klin Wochenschr. 2001. PMID: 15506048 Review. German.
-
[Treatment of focal dystonia with botulinum toxin A].Wien Klin Wochenschr. 2001;113 Suppl 4:6-10. Wien Klin Wochenschr. 2001. PMID: 15506045 Review. German.
Cited by
-
Ixcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection.Funct Neurol. 2017 Apr/Jun;32(2):103-110. doi: 10.11138/fneur/2017.32.2.103. Funct Neurol. 2017. PMID: 28676144 Free PMC article.
-
Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Lower Limb Spasticity.Medicine (Baltimore). 2016 Jan;95(2):e2468. doi: 10.1097/MD.0000000000002468. Medicine (Baltimore). 2016. PMID: 26765447 Free PMC article.
-
AbobotulinumtoxinA Doses in Upper and Lower Limb Spasticity: A Systematic Literature Review.Toxins (Basel). 2022 Oct 26;14(11):734. doi: 10.3390/toxins14110734. Toxins (Basel). 2022. PMID: 36355984 Free PMC article.
-
AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis.Clinicoecon Outcomes Res. 2015 Sep 9;7:441-9. doi: 10.2147/CEOR.S86355. eCollection 2015. Clinicoecon Outcomes Res. 2015. PMID: 26392782 Free PMC article.
-
Systematic literature review of abobotulinumtoxinA in clinical trials for adult upper limb spasticity.Am J Phys Med Rehabil. 2015 Mar;94(3):229-38. doi: 10.1097/PHM.0000000000000208. Am J Phys Med Rehabil. 2015. PMID: 25299523 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical